Amneal Retained Earnings Total Equity from 2010 to 2024
AMRX Stock | USD 8.10 0.05 0.61% |
Retained Earnings Total Equity | First Reported 2017-12-31 | Previous Quarter -413.1 M | Current Value -401.2 M | Quarterly Volatility 150.3 M |
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
Amneal | Retained Earnings Total Equity |
Latest Amneal Pharmaceuticals,'s Retained Earnings Total Equity Growth Pattern
Below is the plot of the Retained Earnings Total Equity of Amneal Pharmaceuticals, Class over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Amneal Pharmaceuticals,'s Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
Retained Earnings Total Equity | 10 Years Trend |
|
Retained Earnings Total Equity |
Timeline |
Amneal Retained Earnings Total Equity Regression Statistics
Arithmetic Mean | (138,723,478) | |
Geometric Mean | 0.00 | |
Coefficient Of Variation | (126.68) | |
Mean Deviation | 163,678,840 | |
Median | 0.00 | |
Standard Deviation | 175,732,961 | |
Sample Variance | 30882.1T | |
Range | 406.2M | |
R-Value | (0.85) | |
Mean Square Error | 8997.1T | |
R-Squared | 0.73 | |
Significance | 0.000051 | |
Slope | (33,561,569) | |
Total Sum of Squares | 432349T |
Amneal Retained Earnings Total Equity History
About Amneal Pharmaceuticals, Financial Statements
Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Retained Earnings Total Equity | -365.6 M | -347.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.